Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial

BACKGROUND: There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubici...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimani, Stephen, Painschab, Matthew S, Kaimila, Bongani, Kasonkanji, Edwards, Zuze, Takondwa, Tomoka, Tamiwe, Mulenga, Maurice, Nyasosela, Richard, Chikasema, Maria, Mtangwanika, Asekanadziwa, Chawinga, Mena, Mhango, Wilberforce, Nicholas, Simon, Chimzimu, Fred, Kampani, Coxcilly, Krysiak, Robert, Lilly, Amy, Randall, Cara, Seguin, Ryan, Westmoreland, Katherine D, Montgomery, Nathan D, Fedoriw, Yuri, Gopal, Satish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338824/
https://www.ncbi.nlm.nih.gov/pubmed/34022150
http://dx.doi.org/10.1016/S2214-109X(21)00181-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338824/
https://www.ncbi.nlm.nih.gov/pubmed/34022150
http://dx.doi.org/10.1016/S2214-109X(21)00181-9

Ejemplares similares